Insurance company Aetna has revised its coverage policy to cover exams performed with the PET radiotracer gallium-68 DOTATATE, marketed as Netspot by Advanced Accelerator Applications.
The decision follows concerns presented by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in a letter to Aetna. Netspot is medically necessary for the diagnosis, staging, and restaging of persons with neuroendocrine tumors, according to the organization.
